(Q40689207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Immunotherapy of multiple sclerosis: where are we? Where should we go? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

Stürzebecher CS

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

McFarland HF

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 September 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

785-788

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis (first of two parts).

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Multiple sclerosis (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Immunological aspects of demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

The T lymphocyte in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Genetic models for CNS inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

Multiple Sclerosis: Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

inferred from DOI database lookup

7 January 2021

based on heuristic

An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

inferred from DOI database lookup

7 January 2021

based on heuristic

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1038%2FNI0901-785

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NI0901-785

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11526386%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference